Akero Therapeutics Inc. priced its IPO of 5.75 million shares at $16 per share for gross proceeds of $92 million.
Atreca Inc. priced its IPO of 7.35 million shares at $17 each for gross proceeds of about $125 million.
Biohaven Pharmaceutical Holding Co. Ltd. priced an underwritten public offering for expected gross proceeds of approximately $300 million.
Bridgebio Pharma Inc. has sets terms for its IPO and plans to sell up to 17.25 million shares priced between $14 and $16 each.
Calithera Biosciences Inc. priced its underwritten public offering for expected gross proceeds of $50 million.
Comet Therapeutics Inc. has raised $28.5 million in series A financing.
Contravir Pharmaceuticals Inc. priced a public offering with expected gross proceeds of about $15.6 million.
Hansoh Pharmaceutical Group Co. Ltd. raised $1 billion on Hong Kong's stock market selling around 551 million shares at HK$14.26 each, the top end of the range.
Imcyse SA raised €28 million (US$31.4 million) in a series B round.
Karuna Therapeutics Inc. has established terms for an IPO and will offer up to 4.375 million shares in the price range between $15 and $17.
Kura Oncology Inc. priced an underwritten public offering that is expected to gross $100.3 million.
Nevakar Inc. entered a $50 million product financing agreement with an affiliate of Novaquest Capital Management LLC.
Prometic Life Sciences Inc. completed its equity rights offering, raising CA$37.99 million (US$28.35 million).
Rapt Therapeutics Inc. has extended its series C financing by securing an additional $37 million.
Rockwell Medical Inc. priced its underwritten public offering for gross proceeds of approximately $17.5 million.
Scholar Rock Holding Corp. priced a public offering for gross proceeds of $45 million.
Stoke Therapeutics Inc. priced its upsized IPO of approximately 7.9 million common shares at $18 apiece, above its proposed range of $14 to $16, expecting to raise approximately $142 million.
Viela Bio Inc. completed a $75 million private placement of its series B preferred stock.
Beigene Ltd. and Springworks Therapeutics Inc. have formed Mapkure LLC to develop BGB-3245, a preclinical oral small-molecule inhibitor of monomer and dimer forms of activating BRAF mutations, including V600 BRAF mutations, non-V600 BRAF mutations and RAF fusions.
CASI Pharmaceuticals Inc. signed an agreement for exclusive worldwide license and commercialization rights to an autologous anti-CD19 T-cell therapy product, CNCT-19, from Juventas Cell Therapy Ltd.
Catalent Inc. has agreed to purchase the oral solid, biologics and sterile product manufacturing and packaging facility in Anagni, Italy, owned by Bristol-Myers Squibb Co.
Gilead Sciences Inc. has agreed to pay Nurix Therapeutics Inc. $45 million up front and as much as $2.3 billion in milestones to discover, develop and commercialize several new drugs for cancer and other challenging diseases.
Immunophotonics Inc. and Clinical Laserthermia Systems AB have agreed to support a phase Ib/IIa trial for cancer patients with certain solid tumor indications.
Pfizer Inc. is acquiring Array Biopharma Inc. and paying $48 per share in cash in a deal with an enterprise value of about $11.4 billion.
Sanofi SA has allied with Google (Alphabet Inc.) to establish a virtual innovation lab designed to tap into emerging data technologies to improve understanding of patients and diseases and increase Sanofi's operational efficiency.
Seven and Eight Biopharmaceuticals Inc. has signed a clinical research collaboration agreement with Roche Holding AG to explore the combination of BDB-001, an immune modulator targeting Toll-like receptors 7 and 8, and atezolizumab, a monoclonal antibody against checkpoint target PD-L1, in treating solid tumors.
Tessa Therapeutics Ltd. and China-Singapore Guangzhou Knowledge City are committing a combined $120 million to establish a joint venture to advance cell therapies targeting prevalent cancers in China.
Theravance Biopharma Ireland Ltd. is expanding its development and commercialization agreement with Mylan NV for nebulized revefenacin to include China and certain adjacent territories.
Ultragenyx Pharmaceutical Inc. and Arcturus Therapeutics Holdings Inc. said they expanded their 2015 collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets.
Voyager Therapeutics Inc. said the Genzyme unit of Sanofi SA has returned rights to the VY-HTT01 Huntington's disease program and ex-U.S. rights to the VY-FXN01 Friedreich's ataxia program.
Anchiano Therapeutics Ltd. completed the process to voluntarily delist its ordinary shares from trading on the Tel Aviv Stock Exchange. Its American depositary shares continue to trade on Nasdaq under the ticker ANCN.
Astrazeneca plc said it will invest $630 million over the next five years in South Korea's health care industry, marking the largest-ever investment by a foreign pharma company in Korea.
Mill Creek Life Sciences LLC received a one-year $100,000 grant from Regenerative Medicine Minnesota to develop technology for the large-scale production of a dendritic cell vaccine to treat glioblastoma multiforme.
Probiodrug AG announced it is changing its name to Vivoryon Therapeutics AG.
Spero Therapeutics Inc. signed a collaboration with the Bill & Melinda Gates Medical Research Institute to develop SPR-720 for the treatment of lung infections caused by Mycobacterium tuberculosis.
The public-private university hospital consortium Dhune, from the Provence-Alpes-Côte d'Azur region, reported the creation of a seed capital fund dedicated exclusively to life sciences, amounting to $112 million.
Theratechnologies Inc. said it will pursue the development of tesamorelin for the treatment of nonalcoholic steatohepatitis in people living with HIV.